Online citations, reference lists, and bibliographies.
← Back to Search

Elicitation Of Utility Scores In Canada For Immune Thrombocytopenia Treated With Romiplostim Or Watch And Rescue

M. Iskedjian, A. Tinmouth, D. Arnold, R. Deuson, J. Isitt, J. Mikhael
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Abstract Objectives: The objective of this study was to obtain utilities, or preference-based quality-of-life values, from the Canadian general public, for potential health states experienced by immune thrombocytopenia (ITP) patients receiving either romiplostim (a new thrombopoietin mimetic agent) or ‘watch and rescue’ therapy. Utilities are needed to conduct a cost-utility analysis of romiplostim for formulary and reimbursement decisions. Methods: An electronic Time Trade-off (TTO) survey was developed and administered to a sample of the general public in Canada, with 12 distinct health states derived from two randomized clinical trials of romiplostim vs watch and rescue treatment. Two pilot tests assessed interpretability and respondent burden. In the final survey, each subject was administered the TTO for four randomly-selected health states. Descriptive statistics were computed for utility scores, and differences between health states were evaluated with an analysis of variance model. Results: Eight hundred and twenty-one adults completed the TTO survey. Mean age was 36.4 (SD = 15) years; 63% were female. Mean (SD) utility scores ranged from 0.476 (0.271) for the most severe health state (significant bleeding) to 0.633 (0.282) for the least severe health state depicting successful treatment with romiplostim. Statistical significance was found on the mean difference between the most severe health state and five other health states (p < 0.05). After adjusting utilities for matching Canadian demographic parameters, no substantial difference was found between original utility scores and adjusted scores. Conclusions: This study provides evidence of the Canadian general public’s preference for 12 ITP health states pertaining to romiplostim treatment or watch and rescue. This study had a number of limitations, the main ones being the lack of perfect match in demographics between this sample and the Canadian population, as well as the fact that the scenario descriptions were based on both published literature and expert opinion. Despite those limitations, the obtained utility scores may be used in cost-utility models of romiplostim as a treatment for ITP patients in Canada.
This paper references
Thrombocytopenia. I. Incidence and aetiology.
L. E. Böttiger (1972)
The utility of different health states as perceived by the general public.
D. Sackett (1978)
L. Gordon (1985)
Utility approach to measuring health-related quality of life.
G. Torrance (1987)
Methodology for measuring health-state preferences--I: Measurement strategies.
D. Froberg (1989)
Protein A immunoadsorption column versus splenectomy in the treatment of steroid-resistant immune thrombocytopenic purpura. A cost-effectiveness analysis.
K. Kunz (1996)
Cost-effectiveness in health and medicine
M. Gold (1996)
Identifying and Valuing Outcomes
D. Patrick (1996)
The incidence of idiopathic thrombocytopenic purpura in adults increases with age.
H. Frederiksen (1999)
User Preferences for Computer Administration of Quality of Life Instruments*
J. Crawley (2000)
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
Yoram Cohen (2000)
Evaluating Health‐Related Quality of Life: Cost Comparison of Computerized Touch‐Screen Technology and Traditional Paper Systems
J. Lofland (2000)
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.
J. Portielje (2001)
Immune thrombocytopenic purpura.
D. Cines (2002)
Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults
D. Provan (2002)
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients
A. J. Neylon (2003)
Health outcomes assessment in vulnerable populations: measurement challenges and recommendations.
E. Hahn (2003)
Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents
D. Barnard (2003)
Adjusting distributions of the Health Utilities Index Mark 3 utility scores of health-related quality of life
Jian Sun (2004)
Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy.
P. Andersson (2004)
The discovery and role of ADAM33, a new candidate gene for asthma.
J. Holloway (2004)
Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
K. Ramadan (2005)
Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease
B. Zeller (2005)
Time Trade-Off Technique †
A. Gafni (2005)
Management of adult idiopathic thrombocytopenic purpura.
D. Cines (2005)
Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura.
H. Ren (2006)
Touch-screen computer systems in the rheumatology clinic offer a reliable and user-friendly means of collecting quality-of-life and outcome data from patients with rheumatoid arthritis.
M. C. Greenwood (2006)
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation
S. Mathias (2007)
A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
S. Mathias (2007)
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
D. Arnold (2007)
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
S. Mathias (2008)
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
J. Stockman (2008)
Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura
R. McMillan (2008)
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials
J. George (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
F. Rodeghiero (2009)
Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura
A. Szende (2010)
V. Cope (2013)
Canadian Agency for Drugs and Technologies in Health. Procedure for common drug review

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar